Affordable Access

Access to the full text

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia

Authors
  • Hamina, Aleksi1, 2, 3
  • Tanskanen, Antti3, 4, 5
  • Tiihonen, Jari3, 4, 5
  • Taipale, Heidi1, 3, 6
  • 1 School of Pharmacy, University of Eastern Finland, Kuopio, Finland
  • 2 Norwegian Centre for Addiction Research (SERAF) Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • 3 Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio
  • 4 Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
  • 5 Department of Clinical Neuroscience, Karolinska Institutet
  • 6 Center for Psychiatric Research, Stockholm City Council, Stockholm, Sweden
Type
Published Article
Journal
Medical Care
Publisher
Lippincott Williams & Wilkins
Publication Date
Jul 23, 2020
Volume
58
Issue
9
Pages
763–769
Identifiers
DOI: 10.1097/MLR.0000000000001369
PMID: 32732784
PMCID: PMC7497420
Source
PubMed Central
Keywords
License
Green

Abstract

Background: Increases in prescription drug cost-sharing may decrease adherence to treatment among persons with schizophrenia and lead to discontinuation of use and an increased risk of hospitalization. Objective: The objective of this study was to investigate the impact of new deductible and increased drug copayments implemented on antipsychotic and other drug purchases and on rates of hospitalizations and primary care contacts among persons with schizophrenia in Finland. Research Design: Interrupted time series analysis. Subjects: All persons with schizophrenia in Finland who were alive at the beginning of 2015 (N=41,017). Measures: We measured the rates of antipsychotic, other psychotropic and cardiometabolic drug purchasers, hospitalizations, and primary care contacts during 2015 and 2016 with data collected from several nationwide health care registers. Results: During 2016, the proportion of antipsychotic purchasers decreased by −0.26 percentage points per month [95% confidence interval (CI): −0.47 to −0.05] compared with 2015. The trend of other psychotropic purchasers decreased to −0.13 percentage points per month in 2016 (95% CI: −0.22 to −0.04) compared with 2015 and cardiometabolic drug purchases to −0.17 percentage points per month (95% CI: −0.29 to −0.05) compared with 2015. The decreasing trend of psychiatric hospitalizations in 2015 halted in 2016. There were no other significant differences in health care utilization. Conclusions: In our nationwide time-series analysis, we observed decreases in the slopes of antipsychotic and other drug purchases of persons with schizophrenia after prescription drug cost-sharing increase implementation on January 1, 2016. Policymakers need to be aware of the unintended consequences of increasing cost-sharing among people with severe mental disorders.

Report this publication

Statistics

Seen <100 times